← Back to Search

Monoclonal Antibodies

ADG106 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Adagene Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose (cycle 1 day 1, each cycle is 21 days) until the last dose (up to 2 years)
Awards & highlights

Study Summary

This study is evaluating whether a drug called ADG106 can be safely given to people with cancer.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose (cycle 1 day 1, each cycle is 21 days) until the last dose (up to 2 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose (cycle 1 day 1, each cycle is 21 days) until the last dose (up to 2 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants experiencing clinical and laboratory adverse events (AEs)
Number of participants experiencing dose-limiting toxicities
Secondary outcome measures
Lowest plasma concentration (C[trough])
Maximum concentration (Cmax)
The area under the curve (AUC) of plasma concentration of drug
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ADG106 Dose escalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADG106
2018
Completed Phase 1
~120

Find a Location

Who is running the clinical trial?

Adagene IncLead Sponsor
10 Previous Clinical Trials
892 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
2018. "Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03707093.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top